NCR3 and neoplasm: Three weeks after injection (designated as ‘start point’), tumor growth was assessed by the CCCD camera and those mice expressing tumors that were large enough for transmitting an integrated signal intensity of 100 photon counts and above, were chosen for further treatment with NKp30-Ig (n = 16), NKp46D2-Ig (n = 9) or with PBS as control (n = 8).